Home » Market News » DirectorsTalk Highlights » EpiSwitch technology has validated biomarkers in a wide range of diseases
Oxford BioDynamics

EpiSwitch technology has validated biomarkers in a wide range of diseases

ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain, a

OBD programme is focused on a development of Alzheimer’s specific biomarkers for several applications.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS, Alzheimer’s and other diseases.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.